Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Exact Sciences Corp (EXAS) Stock: D E Shaw Slightly Lowers Its Stake

According to a recent 13G filing with the SEC, D E Shaw, founded by billionaire David E. Shaw, has slightly lowered its stake in Exact Sciences Corp (NASDAQ:EXAS), as it now holds 5.41 million common shares of the company, which account for 5% of its float. The current stake has been lowered from 5.44 million shares owned on August 15, which represented 5% of the company’s outstanding stock, as reported in the fund’s previous 13G filing on the company.

Exact Sciences is a molecular diagnostics company with a focus on the early detection and prevention of various types of cancer. Over the past 12 months, the company’s shares have increased by an eye-popping 129.09%. For the second quarter of 2016, Exact Sciences disclosed a loss per share of $0.46 and revenue of $21.19 million, both topping analysts’ estimates, which had called for a loss per share of $0.55 and revenue of $18.54 million.

D. E. Shaw

The number of hedge funds long Exact Sciences (NASDAQ:EXAS) stood at 16 at the end of June among those in our database, same as a quarter earlier. Some of the bullish investors included Mark Coe’s Coe Capital Management, which held a position worth $829.17 million, Spencer M. Waxman’s Shannon River Fund Management, with a position valued at $14.09 million, Steve Cohen’s Point72 Asset Management, Charles Paquelet’s Skylands Capital, and Ken Griffin’s Citadel Investment Group.

Follow Exact Sciences Corp (NASDAQ:EXAS)
Trade (NASDAQ:EXAS) Now!

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
D. E. Shaw Co. 0 5,402,130 0 5,410,030 5,410,030 5.0%
David E. Shaw 0 5,402,130 0 5,410,030 5,410,030 5.0%

David E. Shaw
David E. Shaw
D E Shaw

Page 1 of 6 – SEC Filing



Washington, D.C. 20549




Under the Securities Exchange Act of 1934


Exact Sciences Corporation

(Name of Issuer)

Common stock, par value $0.01

(Title of Class of Securities)




(CUSIP Number)



September 27, 2016

(Date of Event Which Requires Filing of
this Statement)

Check the following box to designate the rule pursuant to which
the Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Exact Sciences Corp (NASDAQ:EXAS)
Trade (NASDAQ:EXAS) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.